R D Kenagy

Plain English
This study looked at a protein called PRG4 and its effects on human vein cells, specifically how it influences cell movement and division. The researchers found that PRG4 can slow down the movement of certain vein cells and stop the division of endothelial cells that line blood vessels, but it was not effective in preventing growth in whole veins. This is important because it suggests that low levels of PRG4 might contribute to issues like vein graft failures and varicose veins, hinting at new avenues for treatment. Who this helps: Patients with vein-related problems, including those undergoing vein graft surgery.

Plain English
The study looked at the levels of a specific protein called anti-phosphorylcholine IgM (anti-PC IgM) in patients undergoing leg bypass surgery, which is done to improve blood flow in patients with blocked arteries. Researchers found that 35.2% of the bypass grafts failed within 1.8 years, and those with low levels of anti-PC IgM had double the risk of graft failure compared to others. This matters because measuring anti-PC IgM could help identify patients at risk for complications and lead to better treatments to prevent these failures. Who this helps: Patients undergoing leg bypass surgery.

Plain English
The researchers studied the response of smooth muscle cells (the cells that help veins work) in the valves of human veins compared to other areas without valves. They found that smooth muscle cells in the valve regions were more active: they proliferated 19.3% compared to 6.8% in nonvalve areas and migrated more (18.2 cells compared to 7.5 cells from each explant after six days). This increased activity is important because it may help explain why vein valves are more likely to develop problems like scarring or blood clots. Who this helps: This helps patients with vein conditions and doctors who treat them.

Plain English
This study investigated how factors like leg health, smoking, and diabetes affect the behavior of cells in saphenous veins used for arterial bypass surgery. Researchers found that cells from the outer layer of the vein grew more quickly when the leg had little to no injury or infection, while issues like chronic ischemia (poor blood flow) significantly slowed cell growth. These findings highlight the importance of the condition of the donor leg on the success of vein grafts, suggesting that healthier leg conditions lead to better healing and graft performance. Who this helps: This research benefits patients undergoing bypass surgery and their doctors by informing treatment decisions.

Plain English
This study looked at a protein called versican and another substance called hyaluronan in human vein grafts to understand how they change in different layers of the veins when adapting to the body’s arterial system. The researchers found that versican levels were higher in the inner layers of the vein (30-40% more after 14 days) but remained stable in the outer layer, while hyaluronan levels did not change. These findings are important because they show how specific proteins behave differently in various parts of the vein, which could impact the success of vein grafts in patients. Who this helps: This helps patients undergoing vein graft procedures.

Plain English
Researchers studied a genetic variation in a gene called p27 that controls cell growth, which previous studies linked to vein grafts failing after bypass surgery. They compared cells from different parts of the vein and found that people with the protective genetic variant had more p27 protein, which slowed the growth of outer vein cells but didn't affect the inner muscle cells. This matters because it identifies which part of the vein (the outer layer) is responsible for graft failure, pointing doctors toward new ways to prevent failed vein grafts by targeting growth in that specific layer.

Plain English
Surgeons use marking pens containing crystal violet dye on veins during bypass graft surgery to prevent the vein from twisting. Researchers tested whether this dye affects how well the vein heals after surgery by examining human veins marked with the dye compared to unmarked veins in the lab. The dye significantly slowed the growth and movement of cells in the outer layer of the vein—two processes critical for the vein to heal properly after being transplanted—but the dye didn't reach the inner layer so it didn't affect those cells. This finding matters because it suggests surgeons should find a different, safer way to mark veins during bypass surgery, since the current marking method may compromise how well the transplanted vein functions long-term.

Plain English
Researchers studied cells from veins that were surgically transplanted to bypass blocked arteries, comparing cells from grafts that failed (narrowed and blocked) versus those that stayed open. They analyzed which genes were active in these cells and found two specific genes—SCARA5 and SBSN—that appear to control networks of other genes linked to graft failure; blocking SCARA5 made cells multiply faster, while blocking SBSN reduced the cells' ability to contract and remodel tissue. This matters because about 30% of these vein grafts fail within a few years, and identifying these key genes could lead to new treatments to prevent that failure and keep grafts open longer.

Plain English
This study looked at how a specific genetic variant in the p27(Kip1) gene affects the success of lower extremity vein bypass grafts in 204 patients. They found that patients with the AA version of this gene were more likely to have their grafts working well after three years, with a 75% success rate compared to 55% for those with other versions. This finding is important because it highlights how genetics can influence the effectiveness of a common procedure aimed at improving blood flow in people with severe leg issues. Who this helps: This research benefits patients undergoing vein bypass surgery and their doctors by providing insights into genetic factors that may affect surgical outcomes.

Plain English
Researchers discovered that a cell surface receptor called syndecan-1 works with a protein called Topors to slow down cell growth and block a growth-promoting signal called PDGF-B. They found this by identifying where these two proteins bind together and then removing Topors from cells to see what happened. This matters because understanding how syndecan-1 puts the brakes on cell growth could lead to new treatments for diseases where cells grow out of control, like cancer.

Plain English
Researchers studied two different ways that blood vessels shrink and weaken—one caused by high blood flow through grafts and another caused by tight wrapping around arteries—and found that seven specific genes are activated in both situations. These activated genes produce enzymes that break down the structural material holding blood vessel cells together, and the researchers discovered that when vessel cells die, these same genes turn on, suggesting the body is deliberately dismantling the vessel's structure as the cells die. This discovery identifies specific genes that control how blood vessels deteriorate, which could eventually lead to new treatments to prevent or slow this dangerous weakening of blood vessels used in surgery.

Plain English
Researchers studied how a chemical messenger called nitric oxide changes the behavior of muscle cells in blood vessel walls by modifying a protein called VASP. They found that when nitric oxide phosphorylates (adds a chemical tag to) VASP at a specific location, it weakens the muscle cells' ability to contract and squeeze collagen fibers, while simultaneously making them more likely to invade surrounding tissue. This matters because these same processes go wrong in diseases like atherosclerosis and pulmonary hypertension, where abnormal muscle cell behavior damages blood vessels—so understanding how nitric oxide controls muscle cells through this VASP mechanism could lead to new treatments.

Plain English
Researchers grew cells from vein grafts taken from 18 patients—11 whose grafts stayed healthy and 7 whose grafts narrowed—and tested how aggressively these cells multiplied when exposed to growth-triggering chemicals. Cells from grafts that failed grew much faster in response to these chemicals, and importantly, they ignored heparin (a drug that normally slows cell growth), while cells from successful grafts responded to it. This means some patients' vein graft cells are naturally more aggressive growers that resist treatment, which could explain why certain people's grafts fail while others succeed, and points to potential new ways to prevent graft failure by targeting these overgrown cells.

Plain English
Researchers studied what happens when blood flows too fast through synthetic blood vessel grafts in baboons and found that high flow speeds up the death of muscle cells in the graft's inner lining while triggering the production of a protein-cutting enzyme called ADAMTS4. When they exposed muscle cells in the lab to a death-triggering signal, both the ADAMTS4 enzyme and cell death increased about five-fold, suggesting that this enzyme cuts up a structural protein called versican, which then causes the muscle cells to die and the graft tissue to shrivel. This matters because it could explain why artificial blood vessel grafts sometimes fail—understanding this death mechanism might lead to treatments that prevent the enzyme from destroying the graft or keep muscle cells alive longer.

Plain English
Researchers studied a protein called syndecan-1 that sits on the surface of cells in blood vessel walls to understand whether it prevents dangerous thickening inside arteries after injury. They found that mice lacking this protein developed severe artery blockages after injury because their muscle cells multiplied out of control, while normal mice with the protein stayed healthy—suggesting syndecan-1 acts as a natural brake on cell growth. This discovery matters because it identifies a potential new target for preventing heart attacks and strokes caused by artery narrowing, or for improving treatments like stent placement.

Plain English
Researchers reviewed a new way to treat clogged blood vessels: instead of trying to prevent blockages from forming, they propose shrinking blockages that have already developed by killing the cells that make up the blockage and breaking down the scar tissue around them. Early experiments show this approach works—antibodies that block certain growth signals shrank blockages in artificial grafts, and blood pressure medications triggered the walls of arteries to shrink in animal studies. This matters because one-third of all reconstructed blood vessels eventually narrow, and treating only the vessels that actually develop problems (rather than trying to prevent all of them) could be a simpler and more practical solution.

Plain English
Researchers wrapped baboon arteries with plastic material to see if they could shrink thickened artery walls, testing whether increased blood flow would help or hurt this process. Wrapping the arteries—especially tightly—caused the artery walls to shrink by 28-45% after 28 days, and this worked equally well whether blood flow was normal or doubled. This matters because arterial thickening is a major problem after surgery and in disease, and if doctors can deliberately shrink these thickened areas using a simple wrapping technique, they might have a new way to treat patients without drugs.

Plain English
This study focused on versican, a protein found in blood vessel walls, and how it breaks down during vascular injury or in advanced heart disease. Researchers found that versican is present in both healthy and diseased blood vessels, often in smaller pieces that still perform various functions. Understanding how versican is modified can provide important insights into how blood vessels behave in both healthy and unhealthy conditions. Who this helps: This benefits patients with vascular diseases and their doctors.

Plain English
Researchers studied how a protein called PDGF makes smooth muscle cells in blood vessels grow and multiply, and discovered that PDGF actually works by triggering a second protein called FGF to do the real job of spurring cell growth. This matters because understanding this hidden two-step process could help doctors prevent restenosis—the dangerous re-narrowing of arteries after procedures like stent placement or angioplasty.

Plain English
Researchers placed synthetic grafts in baboons and then increased blood flow through them, which caused the thick inner lining of the grafts to shrink away. They discovered that high blood flow triggered cells in the grafts to produce a protein called BMP4, which stopped smooth muscle cells from multiplying and caused them to die—explaining why the graft lining shrank. BMP4 appears to be the main driver of this shrinkage process, and blocking it reversed the effect. --- **Why it matters:** This finding could lead to better synthetic blood vessel grafts that last longer, since understanding what causes them to deteriorate is the first step toward preventing it.

Plain English
Researchers studied how a protein called PDGF-BB makes muscle cells in blood vessels multiply, and discovered it works by triggering the release of another protein called bFGF that then activates a receptor called FGFR-1. When they blocked bFGF or FGFR-1 in their experiments, the cells stopped multiplying in response to PDGF-BB, proving this chain of events was essential. This matters because understanding how blood vessel muscle cells multiply could lead to treatments for conditions like atherosclerosis and restenosis (when arteries re-narrow after stent placement), both driven by excessive muscle cell growth in vessel walls.

Plain English
Researchers implanted synthetic blood vessel grafts in baboons and discovered that the tissue layer growing inside these grafts changes its composition depending on blood flow speed—normal flow causes a buildup of spongy, water-absorbing molecules (like versican), while high-speed flow triggers the breakdown and loss of these same molecules, causing the overgrown tissue to shrink back down. This matters because excessive tissue growth inside synthetic grafts is a major reason these implants fail in patients, and understanding how blood flow controls this growth could lead to new treatments that either prevent the dangerous buildup or trigger its reversal.

Plain English
Researchers studied how thrombin (a blood-clotting protein) causes muscle cells in blood vessels to multiply and move around—a process that can lead to dangerous buildup inside arteries. They found that thrombin triggers these cells to release a growth factor called bFGF, which then activates two receptor proteins (syndecan-4 and FGFR-1) that work together to make the cells divide and migrate. This matters because understanding exactly how thrombin causes blood vessel cells to proliferate could lead to new drugs that block this process and prevent heart attacks and strokes caused by arterial blockages.

Plain English
Researchers studied how a protein called MMP-9 affects the ability of muscle cells to squeeze and contract collagen (a structural material in blood vessels), which is what happens during dangerous vessel narrowing after angioplasty. They found that MMP-9 has a surprising dual role: at low levels it actually increases contraction, but at high levels it prevents it—and this effect has nothing to do with MMP-9's known ability to break down proteins. This matters because it explains why MMP-9 can protect against vessel re-narrowing after angioplasty and could lead to new treatments that exploit this protein's protective effect.

Plain English
In this study, researchers looked at how thrombin and factor Xa (FXa) affect the growth of human vascular smooth muscle cells. They found that thrombin increased DNA synthesis by 3.3 times and FXa by 2.6 times. This growth occurs through the release of a protein called basic fibroblast growth factor (bFGF), which helps stimulate cell proliferation, and can be blocked by heparin, showing a potential way to limit excessive cell growth related to vascular issues. Who this helps: This research benefits patients with cardiovascular conditions by providing insights into potential treatments for abnormal cell growth in blood vessels.

Plain English
This study looked at how blocking two specific receptors (PDGF receptor alpha and beta) could shrink the thick layer that builds up inside blood vessels after surgery (called intimal hyperplasia) in baboons. The researchers found that using both blockers together reduced the thickness of this layer by 44% and significantly decreased the growth of smooth muscle cells, while increasing cell death. This could lead to new treatments that help prevent or reduce this buildup in patients who have had blood vessel surgery. Who this helps: This helps patients who undergo arterial reconstruction procedures.

Plain English
Researchers found that certain enzymes called MT-MMPs, which are produced by blood vessel cells, can break apart a key protein called FAK that normally holds cells together. When these enzymes were overexpressed in cells, the cells lost their grip on surrounding tissue and moved around more easily—changes that could contribute to dangerous conditions like heart disease and stroke. Blocking these enzymes with a drug prevented the damage to FAK and restored the cells' ability to stick together, suggesting that controlling these enzymes might be a way to treat diseases where blood vessel cells become unstable.

Plain English
Researchers injured arteries in baboons and tested whether blocking a growth protein called PDGF receptor-beta could prevent excessive tissue buildup—a common problem after blood vessel injuries in humans. Blocking this protein worked remarkably well in the first two weeks, stopping both the inner and outer layers of the artery from growing too much, but the effect weakened by week four, suggesting the treatment might not work as a long-term solution. This finding matters because baboons are much closer to humans than the rats typically used in these studies, so it warns doctors that a promising treatment might fail over time in actual patients.

Plain English
This study examined how high blood flow affects certain proteins in grafts used in baboons and whether these changes lead to the degradation of important supportive tissue. Researchers found that after four days of increased blood flow, a protein called urokinase went up, while another, plasminogen activator inhibitor-1, went down. Specifically, after seven days, these conditions led to a significant increase in the breakdown of a protective protein called versican, indicating that enzymes known as serine proteinases are primarily responsible for damaging the grafts. Who this helps: This research benefits doctors and patients using vascular grafts in surgeries.

Plain English
This study looked at how a specific receptor, known as the urokinase receptor, affects the movement and growth of smooth muscle cells in blood vessels taken from baboons. Researchers found that when they blocked this receptor, smooth muscle cells migrated less and grew less, indicating that the receptor is important for cell movement and proliferation in injured arteries. This is important because it helps us understand how blood vessel healing works and could lead to new treatments for cardiovascular diseases. Who this helps: This information can benefit patients at risk for cardiovascular diseases and doctors looking for better treatment methods.

Plain English
This study looked at how increased blood flow affects the growth of smooth muscle cells in grafts used in baboons. Researchers found that increased blood flow led to a significant reduction in the thickness of the neointimal layer (the layer of new cells that form inside the graft), decreasing its size by more than three times. This matters because it reveals how modifying blood flow can influence cell behavior, potentially leading to better outcomes for patients with similar grafts. Who this helps: This helps patients receiving vascular grafts.

Plain English
This study looked at how certain proteins, called metalloproteinases, play a role in the death of human endothelial cells, which line blood vessels, when they don't get enough growth signals. The researchers found that levels of a specific metalloproteinase, MMP2, increased three to four times during cell death, especially when linked to specific proteins called integrins. This information is important because it shows that these proteins might help speed up the process of cell death, which can influence how blood vessels function in health and disease. Who this helps: This findings are beneficial for researchers and doctors working on vascular diseases and treatment strategies.

Plain English
This study examined a protein called versican in the human aorta and identified a specific site where it gets broken down. Researchers found that the enzymes ADAMTS-1 and ADAMTS-4 can cleave versican at the bond between two amino acids, which was confirmed by experiments showing that these enzymes acted on both lab-made and natural versican. Understanding how versican is processed in blood vessels is important for figuring out its role in conditions like blood vessel diseases. Who this helps: This information benefits researchers and healthcare professionals studying vascular health and disease.

Plain English
The study looked at two specific enzymes, MT1-MMP and MT3-MMP, in smooth muscle cells from baboons to understand how they affect cell behavior. It found that while both enzymes have different strengths in breaking down proteins, they can both change how smooth muscle cells look and move, even though they don’t affect how fast the cells grow. This is important because understanding these enzymes could provide insights into heart and blood vessel health. Who this helps: This helps doctors and researchers working on cardiovascular diseases.

Plain English
This study looked at how a specific protein called MMP9 is produced by immune cells known as macrophages, which could affect conditions like heart disease and aneurysms. They found that macrophages grown on a special type of collagen made significantly less MMP9 compared to those grown on plastic and were more responsive to signals that usually trigger MMP9 production. This is important because controlling MMP9 levels in blood vessels could help prevent serious health issues related to plaque buildup and vessel weakness. Who this helps: This research benefits patients at risk of heart disease and aortic aneurysms.

Plain English
This study looked at two specific proteins, MT1-MMP and MT3-MMP, in smooth muscle cells from blood vessels. Researchers found that increasing MT1-MMP levels led to more activation of another protein called MMP-2, while increasing MT3-MMP led to only partial activation. Both proteins caused the cells to change shape, making them stick less to their surroundings and move more easily, which could impact how blood vessels behave after injury. Who this helps: This benefits patients recovering from vascular injuries, as understanding these proteins might lead to better treatments.

Plain English
This study looked at how two proteins, IL-1beta and TNFalpha, impact the movement and growth of smooth muscle cells in the arteries of baboons. The researchers found that these proteins slowed down the movement of these cells and reduced their ability to grow, partially through the production of nitric oxide. These findings are important because they suggest a way to limit excessive cell growth in arteries after injury, which could help improve treatments for conditions like atherosclerosis. Who this helps: This helps patients with artery damage or atherosclerosis.

Plain English
The study looked at a protein called MMP-9 and its effects on smooth muscle cells in injured arteries in rats. Researchers found that when MMP-9 was increased, these cells moved more easily and caused changes in the artery structure, such as a larger circumference and thinner walls. This is important because it could help us understand how blood vessel injuries heal and lead to better treatments for heart disease. Who this helps: This helps patients with vascular injuries and doctors treating cardiovascular diseases.

Plain English
In this study, researchers looked at how increasing a protein called plasminogen activator inhibitor-1 (PAI-1) could prevent the development and rupture of aortic aneurysms in rats. They found that rats treated with the PAI-1 showed significant protection: none of the grafts in this group ruptured or became aneurysmal, compared to 40% rupture in another group where PAI-1 was not administered. This is important because it suggests that blocking certain enzymes could stop dangerous blood vessel bulges from forming and rupturing, potentially saving lives. Who this helps: This helps patients at risk for aneurysms.

Plain English
This study looked at how certain proteins help smooth muscle cells move from baboon aorta tissue after an injury. Researchers found that proteins called bFGF and PDGF, along with enzymes MMP2 and MMP9, are essential for this movement. Specifically, blocking these proteins reduced the movement of muscle cells—highlighting that bFGF and both forms of PDGF can increase this migration, which is important for understanding how blood vessels heal. Who this helps: This helps patients with vascular injuries and doctors looking for treatments to improve blood vessel healing.

Plain English
This study examined how a chemical called BB94 affects the movement and growth of smooth muscle cells in arteries after injury. The researchers found that BB94 reduced the number of smooth muscle cell nuclei in a damaged artery and slowed down thickening of the artery wall, suggesting it may help control this dangerous process. Specifically, they noted that the treatment led to fewer cell nuclei in the intima 14 days after an injury, which is important because excessive thickening can lead to blockages and heart problems. Who this helps: This helps patients at risk of heart disease from artery blockages.

Plain English
This study looked at how certain proteins affect the movement of smooth muscle cells in blood vessels of primates. Researchers found that in lab conditions, more than 90% of the baboon artery samples showed smooth muscle cell migration after about 11 days. Blocking specific proteins reduced this migration, meaning these proteins are important for the movement of these cells, which is key for both normal artery development and disease processes. Who this helps: This benefits patients with cardiovascular diseases by improving understanding of how blood vessels respond to injury.

Plain English
This study examined how certain substances affect the production of important proteins in the cells of baboon arteries. Researchers found that growth factors from platelets and fibroblasts increased the levels of tissue plasminogen activator (tPA), while heparin could either inhibit or enhance this effect depending on the specific conditions. Understanding these interactions is important because they may influence the development of artery-related diseases, such as atherosclerosis. Who this helps: This information benefits doctors and researchers studying heart disease and related conditions.

Plain English
This study looked at how heparin affects certain proteins in artery smooth muscle cells that can break down the surrounding tissue. Researchers found that heparin significantly reduced the production of three specific proteins involved in this process, leading to a decrease in tissue breakdown. Specifically, heparin lowered the levels of collagenase, 92-kD gelatinase, and stromelysin when influenced by another substance, with effects increasing the more heparin was used. Who this helps: This helps patients with arterial conditions by potentially slowing down tissue damage related to artery growth.

Plain English
This study looked at how certain proteins, called matrix metalloproteinases (MMPs), behave in the walls of blood vessels in rats after they suffered an injury from ballooning. The researchers found that specific MMPs increased at certain times: one type rose within 24 hours as the cells began to grow, and another increased by day five when cells started to move. This research is important because it highlights the role of MMPs in the healing process of blood vessels, which could impact strategies for treating vascular diseases or injuries. Who this helps: This helps patients recovering from vascular surgeries or those with blood vessel diseases.

Plain English
This study looked at how heparin, a substance often used as a blood thinner, prevents certain cells in blood vessels from growing and moving too much. The researchers found that heparin works by blocking specific proteins that help these cells expand and travel. Understanding this process is important because it could help in treating conditions where blood vessel growth goes awry, like in heart disease. Who this helps: This helps patients with heart conditions and other vascular diseases.

Plain English
This study looked at how heparin, a common blood thinner, affects the growth and movement of smooth muscle cells in primates. Researchers found that heparin reduces the production of a specific protein called tissue-type plasminogen activator (tPA) in these cells by interfering with the process that activates its gene; specifically, they noted a significant decrease in tPA mRNA levels. This is important because it suggests that heparin may be useful in treating conditions where abnormal smooth muscle growth contributes to vascular diseases. Who this helps: This benefits patients at risk of vascular diseases.

Plain English
This study looked at how certain cells in healing blood vessel grafts are involved in growth factor production, which helps with cell growth and repair. Research on baboons showed that these grafts had higher levels of specific growth factors, particularly platelet-derived growth factor-A, compared to the surrounding artery tissue. Understanding this process is important because it could lead to better graft performance and reduced failure rates. Who this helps: This helps patients needing vascular grafts and their doctors.